Paul Barr, MD of the University of Rochester discusses data presented at the 58th Annual ASH Meeting & Exposition showing the long term efficacy and safety of ibrutinib in elderly patients with chronic lymphocytic leukemia.
Barr PM, Robak T, Owen CJ, et al. Updated Efficacy and Safety from the Phase 3 Resonate-2 Study: Ibrutinib As First-Line Treatment Option in Patients 65 Years and Older with Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia. Presented at the 58th ASH Annual Meeting & Exposition; San Diego, CA: December 3-6, 2016. Abstract 234.